Richard M. Wright
Insider (Form 4 reporting owner): Former Officer CIK 1646423Name as filed: Wright Richard M.Its filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 14 Dec 2020, sold $3.7M in 4 sales of Celldex Therapeutics.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | Former Officer | 14 Dec 2020 | 13 Nov 2025 | – | 4$3.7M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | too few trades4 trades | too few trades4 trades | too few trades4 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2025 | – | – | 1 | $1.2M | -$1.2M |
| 2024 | – | – | 1 | $1.6M | -$1.6M |
| 2022 | – | – | 1 | $578K | -$578K |
| 2020 | – | – | 1 | $388K | -$388K |
Every trade
4, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 13 Nov 2025 | Celldex Therapeutics CLDX | Sellafter exercising options | 49,298 | $24.00 | $1.2M | No | Form 4filed 17 Nov 2025 |
| 3 Jun 2024 | Celldex Therapeutics CLDX | Sellafter exercising options | 46,844 | $33.72 | $1.6M | No | Form 4filed 5 Jun 2024 |
| 15 Aug 2022 | Celldex Therapeutics CLDX | Sellafter exercising options | 15,328 | $37.71 | $578K | Not stated | Form 4filed 17 Aug 2022 |
| 14 Dec 2020 | Celldex Therapeutics CLDX | Sellafter exercising options | 20,832 | $18.61 | $388K | Not stated | Form 4filed 16 Dec 2020 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.